• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Smad7水平升高与克罗恩病术后早期复发有关。

High Smad7 in the early post-operative recurrence of Crohn's disease.

作者信息

Zorzi Francesca, Calabrese Emma, Di Fusco Davide, De Cristofaro Elena, Biancone Livia, Casella Sara, Palmieri Giampiero, Monteleone Giovanni

机构信息

Department of Systems Medicine, University of Rome "Tor Vergata", Via Montpellier 1, 00133, Roma, Italy.

Department of Biomedicine and Prevention, Anatomic Pathology Unit, University of Rome "Tor Vergata", Roma, Italy.

出版信息

J Transl Med. 2020 Oct 19;18(1):395. doi: 10.1186/s12967-020-02558-8.

DOI:10.1186/s12967-020-02558-8
PMID:33076905
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7574182/
Abstract

BACKGROUND

In Crohn's disease (CD), one of the major inflammatory bowel disease (IBD) in human beings, there is over-expression of Smad7, an intracellular inhibitor of the suppressive cytokine TGF-β1. The aim of this study was to assess whether Smad7 over-expression occurs in the early and/or late phases of CD.

METHODS

Mucosal samples were taken from the neo-terminal ileum of CD patients undergoing ileocolonic resection, with or without (early CD) post-operative endoscopic recurrence, and terminal ileum of CD patients with long-standing disease undergoing intestinal resection (late CD). Smad7 was examined by immunohistochemistry and cytokine expression was analysed by flow-cytometry.

RESULTS

Before the appearance of endoscopic lesions, the mucosa of the neo-terminal ileum contained high number of Smad7-expressing cells in both the epithelial and lamina propria compartments. Transition from this stage to endoscopic recurrence was marked by persistence of high number of Smad7-positive cells, which reduced significantly in the late stages of the disease, where Smad7 expression remained, however, greater than that seen in normal controls. In samples with early lesions, Smad7 expression positively correlated with the number of interferon-γ-secreting cells.

CONCLUSIONS

Smad7 induction is an early event in the inflammatory sequence occurring in CD, thus suggesting that knockdown of Smad7 can help prevent post-operative recurrence.

摘要

背景

在人类主要的炎症性肠病(IBD)之一的克罗恩病(CD)中,细胞内抑制性细胞因子TGF-β1的抑制剂Smad7存在过表达。本研究的目的是评估Smad7过表达是否发生在CD的早期和/或晚期。

方法

从接受回结肠切除术的CD患者的新末端回肠获取黏膜样本,这些患者有或没有(早期CD)术后内镜复发,以及从接受肠切除术的患有长期疾病的CD患者的末端回肠获取样本(晚期CD)。通过免疫组织化学检测Smad7,并通过流式细胞术分析细胞因子表达。

结果

在内镜病变出现之前,新末端回肠的黏膜在上皮和固有层中均含有大量表达Smad7的细胞。从这个阶段到内镜复发的转变以大量Smad7阳性细胞的持续存在为标志,在疾病后期这些细胞数量显著减少,然而,Smad7表达仍高于正常对照。在有早期病变的样本中,Smad7表达与分泌干扰素-γ的细胞数量呈正相关。

结论

Smad7的诱导是CD中炎症序列的早期事件,因此表明敲低Smad7有助于预防术后复发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/e911c034f6d6/12967_2020_2558_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/dfd7efed2c64/12967_2020_2558_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/5392bb8e5fd5/12967_2020_2558_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/c2e5a0070993/12967_2020_2558_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/e911c034f6d6/12967_2020_2558_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/dfd7efed2c64/12967_2020_2558_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/5392bb8e5fd5/12967_2020_2558_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/c2e5a0070993/12967_2020_2558_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fb2/7574182/e911c034f6d6/12967_2020_2558_Fig4_HTML.jpg

相似文献

1
High Smad7 in the early post-operative recurrence of Crohn's disease.Smad7水平升高与克罗恩病术后早期复发有关。
J Transl Med. 2020 Oct 19;18(1):395. doi: 10.1186/s12967-020-02558-8.
2
Distinct profiles of effector cytokines mark the different phases of Crohn's disease.效应细胞因子的独特特征标志着克罗恩病的不同阶段。
PLoS One. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562. Epub 2013 Jan 17.
3
Reciprocal Regulation Between Smad7 and Sirt1 in the Gut.肠道中 Smad7 和 Sirt1 的相互调节
Front Immunol. 2018 Aug 10;9:1854. doi: 10.3389/fimmu.2018.01854. eCollection 2018.
4
Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease.阻断Smad7可恢复慢性炎症性肠病中的TGF-β1信号传导。
J Clin Invest. 2001 Aug;108(4):601-9. doi: 10.1172/JCI12821.
5
Smad7 Knockdown Restores Aryl Hydrocarbon Receptor-mediated Protective Signals in the Gut.Smad7基因敲低可恢复肠道中芳烃受体介导的保护信号。
J Crohns Colitis. 2016 Jun;10(6):670-7. doi: 10.1093/ecco-jcc/jjw030. Epub 2016 Jan 27.
6
CCL20 Is Negatively Regulated by TGF-β1 in Intestinal Epithelial Cells and Reduced in Crohn's Disease Patients With a Successful Response to Mongersen, a Smad7 Antisense Oligonucleotide.CCL20 在肠上皮细胞中受 TGF-β1 负调控,并在对 Smad7 反义寡核苷酸 Mongersen 治疗有应答的克罗恩病患者中减少。
J Crohns Colitis. 2017 May 1;11(5):603-609. doi: 10.1093/ecco-jcc/jjw191.
7
Tissue inhibitor of metalloproteinase-3 regulates inflammation in human and mouse intestine.组织金属蛋白酶抑制剂 3 可调节人肠道和鼠肠道的炎症反应。
Gastroenterology. 2012 Nov;143(5):1277-1287.e4. doi: 10.1053/j.gastro.2012.07.016. Epub 2012 Jul 20.
8
Smad7 and its Potential as Therapeutic Target in Inflammatory Bowel Diseases.Smad7及其作为炎症性肠病治疗靶点的潜力。
Curr Drug Metab. 2016;17(3):303-6. doi: 10.2174/1389200217666151210130103.
9
Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer.Smad7 在肠道炎症性疾病和结肠癌中的作用。
Int J Mol Sci. 2021 Apr 10;22(8):3922. doi: 10.3390/ijms22083922.
10
Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis.CYLD 的可变剪接形式介导 SMAD7 的泛素化以防止 TGFB 信号转导并促进结肠炎。
Gastroenterology. 2019 Feb;156(3):692-707.e7. doi: 10.1053/j.gastro.2018.10.023. Epub 2018 Oct 10.

引用本文的文献

1
Colitis-associated carcinogenesis: crosstalk between tumors, immune cells and gut microbiota.结肠炎相关的致癌作用:肿瘤、免疫细胞与肠道微生物群之间的相互作用
Cell Biosci. 2023 Oct 24;13(1):194. doi: 10.1186/s13578-023-01139-8.
2
Smad7 as a positive regulator of intestinal inflammatory diseases.Smad7作为肠道炎症性疾病的正向调节因子。
Curr Res Immunol. 2023 Jan 24;4:100055. doi: 10.1016/j.crimmu.2023.100055. eCollection 2023.
3
Regulatory T cells as a therapeutic approach for inflammatory bowel disease.调节性 T 细胞作为炎症性肠病的一种治疗方法。

本文引用的文献

1
Temporally Distinct Functions of the Cytokines IL-12 and IL-23 Drive Chronic Colon Inflammation in Response to Intestinal Barrier Impairment.细胞因子 IL-12 和 IL-23 的时间特异性功能驱动慢性结肠炎症对肠道屏障损伤的反应。
Immunity. 2019 Aug 20;51(2):367-380.e4. doi: 10.1016/j.immuni.2019.06.008. Epub 2019 Jul 23.
2
Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis.CYLD 的可变剪接形式介导 SMAD7 的泛素化以防止 TGFB 信号转导并促进结肠炎。
Gastroenterology. 2019 Feb;156(3):692-707.e7. doi: 10.1053/j.gastro.2018.10.023. Epub 2018 Oct 10.
3
Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.
Eur J Immunol. 2023 Feb;53(2):e2250007. doi: 10.1002/eji.202250007. Epub 2023 Jan 6.
4
Molecular mechanism of the TGF‑β/Smad7 signaling pathway in ulcerative colitis.TGF-β/Smad7 信号通路在溃疡性结肠炎中的分子机制。
Mol Med Rep. 2022 Apr;25(4). doi: 10.3892/mmr.2022.12632. Epub 2022 Feb 9.
5
Current Trends in IBD-Development of Mucosal-Based Biomarkers and a Novel Minimally Invasive Recoverable Sampling System.当前 IBD 研究的趋势——黏膜生物标志物的发展和一种新型微创可回收采样系统。
Inflamm Bowel Dis. 2021 Nov 15;27(Suppl 2):S17-S24. doi: 10.1093/ibd/izab179.
6
Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer.Smad7 在肠道炎症性疾病和结肠癌中的作用。
Int J Mol Sci. 2021 Apr 10;22(8):3922. doi: 10.3390/ijms22083922.
蒙吉森(GED-0301)治疗活动期克罗恩病患者的内镜和临床结局的影响。
Gastroenterology. 2018 Jan;154(1):61-64.e6. doi: 10.1053/j.gastro.2017.08.035. Epub 2017 Aug 25.
4
Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease.蒙歌根,一种口服 SMAD7 反义寡核苷酸,与克罗恩病。
N Engl J Med. 2015 Mar 19;372(12):1104-13. doi: 10.1056/NEJMoa1407250.
5
Distinct profiles of effector cytokines mark the different phases of Crohn's disease.效应细胞因子的独特特征标志着克罗恩病的不同阶段。
PLoS One. 2013;8(1):e54562. doi: 10.1371/journal.pone.0054562. Epub 2013 Jan 17.
6
Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease.Smad7 反义寡核苷酸敲低治疗活动期克罗恩病的 I 期临床试验。
Mol Ther. 2012 Apr;20(4):870-6. doi: 10.1038/mt.2011.290. Epub 2012 Jan 17.
7
Inflammatory bowel disease.炎症性肠病。
Annu Rev Immunol. 2010;28:573-621. doi: 10.1146/annurev-immunol-030409-101225.
8
The natural history of adult Crohn's disease in population-based cohorts.基于人群队列的成人克罗恩病的自然史。
Am J Gastroenterol. 2010 Feb;105(2):289-97. doi: 10.1038/ajg.2009.579. Epub 2009 Oct 27.
9
Infliximab prevents Crohn's disease recurrence after ileal resection.英夫利昔单抗可预防回肠切除术后克罗恩病复发。
Gastroenterology. 2009 Feb;136(2):441-50.e1; quiz 716. doi: 10.1053/j.gastro.2008.10.051. Epub 2008 Oct 31.
10
TGF-beta1 and Smad7 in the regulation of IBD.转化生长因子-β1和Smad7在炎症性肠病调控中的作用
Mucosal Immunol. 2008 Nov;1 Suppl 1:S50-3. doi: 10.1038/mi.2008.55.